Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health has been chosen to join the Startup Creasphere Digital Health Program
  • Startup Creasphere is a 12-week program in Munich, Germany
  • Here, ResApp will work with experts and mentors to find ways to make more health-focused respiratory disease products
  • The main focus will be ResApp’s smartphone app which can diagnose respiratory disease
  • ResApp is up 14.81 per cent today and shares last traded for 31 cents per share

ResApp Health has been selected to join the Startup Creasphere Digital Health Program in Munich, Germany.

Startup Creasphere, which is powered by Plug and Play, was established in 2018 and is the first health-focused accelerator in Munich.

It provides startups with a platform to receive business development opportunities with leading corporations, mentoring, workshops, office space, capital, and access to its global network.

“We are very excited to participation the Startup Creasphere program to build and pilot a consumer health-focused product using our novel respiratory diagnostic algorithms,” Tony Keating, the CEO and Managing Director of ResApp, said.

“Collaborating with the consumer healthcare business unit of Sanofi during the program provides ResApp with an outstanding opportunity to explore the direct-to-consumer market alongside global industry leaders,” he added.

Under the 12-week program, ResApp’s primary focus will be the development of its smartphone app that can diagnose respiratory disease simply by coughing into a phone.

It has already received TGA approval for its ResAppDx-EU device, and EU CE Mark approval.

ResApp will retain all intellectual property developed under the program.

ResApp is up 14.81 per cent today and shares last traded for 31 cents per share

RAP by the numbers
More From The Market Herald

" Optiscan Imaging (ASX:OIL) signs distribution partnership for China

Optiscan Imaging (OIL) joins forces with a strategic distribution partner in China for its ViewnVivo device.
The Market Herald Video

" Imugene (ASX:IMU) confirms “favourable” survival outcome in HER-Vaxx phase two trial

Imugene (ASX:IMU) has reported positive final overall data from its phase two study of HER-Vaxx in…
The Market Herald Video

" Dimerix (ASX:DXB) closes recruitment for REMAP-CAP study

Dimerix (ASX:DXB) has formally closed recruitment of moderate state COVID-19 patients for REMAP-CAP's renin angiotensin system…
The Market Herald Video

" Starpharma (ASX:SPL) expands research program with Genentech

Starpharma (ASX:SPL) expands its research agreement with Genentech for its drug delivery technology, DEP.